Combination therapy with SGLT2 inhibitors for diabetic kidney disease
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a novel class of oral antihyperglycemic agents developed in recent years. They could block most glucose reabsorption in renal proximal tubules, thereby exerting glucose lowering effects through glycosuric ways. The renal and cardiovascular protec...
Main Authors: | Yuwen Cai, Xin Liu, Gaosi Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-07-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222030384X |
Similar Items
-
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01) -
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01) -
Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis
by: Maria Mirabelli, et al.
Published: (2020-05-01) -
SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01) -
NEW APPROACHES IN THE TREATMENT OF TYPE 2 DIABETES - TRANSITION FROM GLUCOSE-CENTRED TO PATIENT-CENTRED MODEL
by: Antoaneta Tsvetkova, et al.
Published: (2021-08-01)